fbpx For Patients - Plus Therapeutics (PSTV)

At Plus Therapeutics, we seek to help patients and clinicians find safe, lasting solutions for treating rare and difficult-to-treat cancers.

So that adults get to push next month’s plans into next year. Children can live to reach their next big milestone. And families can appreciate their time together without the constant burden of disease and toxicity.

We are focused on an emerging class of cancer therapies called radiotherapeutics.

They’re designed to deliver therapeutic doses of radiation to malignant tumors – either systemically or through a catheter.

Traditionally, radiation has been considered as effective as it is toxic, largely due to the fact that it was never delivered with enough precision. The development of radiotherapeutics is driven by the desire to move away from nonspecific, toxic delivery approaches in favor of more targeted treatments that impact only the cancer tumor.

How we create impact.

We are developing radiotherapeutic programs with the potential to deliver a single, highly powerful radiation dose directly to a tumor without damaging healthy tissue or causing significant side effects.

Precision

Safety

Convenience

Cancer Targets

Recurrent Glioblastoma (GBM)

The deadliest, most common type of brain cancer in adults, primarily due to the treatment-resistant infiltrative nature of the tumor and its location in the brain, which makes drug delivery highly difficult.

Leptomeningeal Metastases (LM)

A rare, typically fatal cancer where tumor cells spread to the central nervous system (CNS), often leading patients to choose between a variety of highly toxic treatments that can prolong life or a less painful life that may end just months from diagnosis.

Pediatric Brain Cancer (PBC)

The second most common type of cancer in children, accounting for approximately 26% of childhood cancers, that often leaves patients with limited options that are not invasive or highly toxic.

Primary Liver Cancer

Known as Hepatocellular Carcinoma (HCC), the most common type of liver cancer with fatty liver disease and cirrhosis as main risk factors, as well as many treatments options, though none significantly prolong survival.

Secondary Liver Cancer

Known as Metastatic Colorectal Cancer (mCRC), an advanced stage IV cancer that spreads to the liver from breast, lung, and colorectal cancers, and is very difficult to treat as many patients are not candidates for resection at diagnosis.

> <

Recurrent Glioblastoma (GBM)

The deadliest, most common type of brain cancer in adults, primarily due to the treatment-resistant infiltrative nature of the tumor and its location in the brain, which makes drug delivery highly difficult.

Leptomeningeal Metastases (LM)

A rare, typically fatal cancer where tumor cells spread to the central nervous system (CNS), often leading patients to choose between a variety of highly toxic treatments that can prolong life or a less painful life that may end just months from diagnosis.

Pediatric Brain Cancer (PBC)

The second most common type of cancer in children, accounting for approximately 26% of childhood cancers, that often leaves patients with limited options that are not invasive or highly toxic.

Primary Liver Cancer

Known as Hepatocellular Carcinoma (HCC), the most common type of liver cancer with fatty liver disease and cirrhosis as main risk factors, as well as many treatments options, though none significantly prolong survival.

Secondary Liver Cancer

Known as Metastatic Colorectal Cancer (mCRC), an advanced stage IV cancer that spreads to the liver from breast, lung, and colorectal cancers, and is very difficult to treat as many patients are not candidates for resection at diagnosis.

Recurrent Glioblastoma (GBM)

The deadliest, most common type of brain cancer in adults, primarily due to the treatment-resistant infiltrative nature of the tumor and its location in the brain, which makes drug delivery highly difficult.

Leptomeningeal Metastases (LM)

A rare, typically fatal cancer where tumor cells spread to the central nervous system (CNS), often leading patients to choose between a variety of highly toxic treatments that can prolong life or a less painful life that may end just months from diagnosis.

Pediatric Brain Cancer (PBC)

The second most common type of cancer in children, accounting for approximately 26% of childhood cancers, that often leaves patients with limited options that are not invasive or highly toxic.

Primary Liver Cancer

Known as Hepatocellular Carcinoma (HCC), the most common type of liver cancer with fatty liver disease and cirrhosis as main risk factors, as well as many treatments options, though none significantly prolong survival.

Secondary Liver Cancer

Known as Metastatic Colorectal Cancer (mCRC), an advanced stage IV cancer that spreads to the liver from breast, lung, and colorectal cancers, and is very difficult to treat as many patients are not candidates for resection at diagnosis.

Our Programs

Rhenium-186 NanoLiposome (186RNL)

Designed to allow for targeted, high-dose beta radiation to brain and CNS cancers via convection enhanced delivery (CED) or the Ommaya reservoir – with limited exposure to surrounding tissue.

Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM)

Designed to cut off the tumor’s blood supply and allow for targeted beta radiation to liver cancers through injection into the hepatic artery.

Now actively recruiting.

ReSPECT™-GBM Phase I/II Clinical Trial

The purpose of the ReSPECTTM Clinical Trial is to assess the safety, tolerability, and distribution of a new medication, Rhenium-186 NanoLiposome (186RNL), in adults with recurrent or progressive malignant glioma after standard surgical, radiation, and/or chemotherapy treatment. ReSPECTTM is supported by the U.S. National Institutes of Health / National Cancer Institute.

Supported by:

Blue NIHRed NIH

Results:

Interim data from the ongoing clinical trial shows that the administration of 186RNL was well-tolerated in adult patients with recurrent GBM at significantly higher doses than with standard treatment modalities, such as external beam radiation therapy (EBRT).

ReSPECT™-LM Phase I Clinical Trial

The purpose of the ReSPECT-LM Clinical Trial is to assess the safety, tolerability, and distribution of our novel radiotherapeutic, 186RNL, in adults with leptomeningeal metastases. The treatment consists of a single dose of 186RNL administered through an intraventricular catheter (Ommaya reservoir).

Results:

Our clinical trial follows preclinical studies in which high doses were tolerated with no observed significant toxicity and treatment led to marked reduction in tumor burden in both glioma and breast cancer LM rat models.

Not yet recruiting.

ReSPECT™-PBC Phase I Clinical Trial

The purpose of the ReSPECT™ Clinical Trial is to assess the safety, tolerability, and distribution of our novel radiotherapeutic, 186RNL, in children with ependymoma and high-grade glioma. The treatment consists of a single dose of 186RNL administered via CED.